Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
← catalyst calendarNCT07755436 · readout ≤ 376 d
Sponsored by ArriVent BioPharma, Inc. (industry) · AVBP — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
180estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-23 | actual | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ovarian Cancer
- Endometrial Cancer
- Platinum-resistant Ovarian Cancer (PROC)
- Metastatic Ovarian Cancer
- Metastatic Endometrial Cancer
Intervention
- Drug: ARR-002
Primary outcomes
what the primary-completion date above is the date OFTreatment-Emergent Adverse Event (TEAE)
measured Baseline to 30 days after the last dose of study treatment
Maximum Tolerated Dose (MTD)
measured Baseline to Day 21 of the first treatment cycle
Permalink · AVBP's whole pipeline · Catalyst calendar · Every registered study · What changed